<DOC>
	<DOCNO>NCT00540709</DOCNO>
	<brief_summary>Whether once-daily basal injection insulin glargine mealtime injection insulin lispro achieves equivalent glycaemic control ( HbA1c ) administration insulin lispro continuous subcutaneous insulin infusion Type 1 diabetic patient .</brief_summary>
	<brief_title>PUMP STUDY MDI Lantus/Lispro v Continuous Insulin+Lispro</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>diagnosis type 1 diabetes mellitus least one year . Subjects previous experience Continuous Subcutaneous Insulin Infusion ( CSII ) insulin glargine , capable manage basalbolus regimen meet glycaemic target accordance protocol . HbA1c &gt; = 6.5 &lt; = 9.0 % screen visit evidence lack insulin secretion ( e.g . fast Cpeptide concentration &lt; 0.1 nmol/l fast blood glucose ( FBG ) &gt; 126 mg/dl ) . Previous therapy use insulin glargine continuous subcutaneous insulin infusion . Lipodystrophy prevent adequate use CSII . Unwilling unlikely able use MiniMedr insulin pump insulin lispro CSII . Unwilling unlikely able use MDI regimen insulin glargine insulin lispro accordance protocol ( instance , subject routinely use twicedaily mixed insulin regimen include ) . History two severe hypoglycaemic episode past 6 month . Acute infection , opinion investigator , could lead increased insulin resistance . Acute chronic metabolic acidosis . Episode DKA ( diabetic ketoacidosis ) within last three month . Active , uncontrolled , advance diabetic retinopathy . Impaired hepatic function , show &gt; 2.5 time upper limit normal range AST . Impaired renal function , show serum creatinine &gt; 1.5mg/dl . History gastroparesis . Congestive heart failure require ongoing pharmacological treatment . Stroke , myocardial infarction ( MI ) , coronary artery bypass graft ( CABG ) , percutaneous transluminal coronary angioplasty ( PTCA ) angina pectoris within last 12 month . Treatment nonselective beta blocker . Treatment inhale systemic steroid . History hypersensitivity insulin lispro drug similar chemical structure insulin glargine insulin lispro excipients insulin glargine insulin lispro preparation use study . Any malignancy within last five year , except adequately treat basal cell carcinoma . History within last two year current addiction substance abuse include ethanol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>